Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I studySarah P. Blagden, Essam Ghazaly, Ivana Rizzuto et al.|British Journal of Cancer|2018Cited by 43
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian CancerFarasat Kazmi, Sarah P. Blagden, René L. Roux et al.|Clinical Cancer Research|2021Cited by 10
Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.Sarah P. Blagden, Christopher McGuigan, Chara Stavraka et al.|Journal of Clinical Oncology|2015Cited by 7
A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers.Sarah P. Blagden, Essam Ghazaly, Nishat Bharwani et al.|Journal of Clinical Oncology|2015Cited by 5
PRO-002, a phase Ib dose-escalation study of NUC-1031 with carboplatin for recurrent ovarian cancerSarah P. Blagden, Essam Ghazaly, Ajithkumar Sukumaran et al.|Annals of Oncology|2017Cited by 2